| Literature DB >> 26541320 |
Daniel A Goldstein1, Simon B Zeichner2, Catherine M Bartnik3, Eli Neustadter2, Christopher R Flowers2.
Abstract
To evaluate, from a US payer perspective, the cost-effectiveness of treatment strategies for metastatic colorectal cancer (mCRC), we performed a systematic review of published cost-effectiveness analyses. We identified 14 papers that fulfilled our search criteria and revealed varying levels of value among current treatment strategies. Older agents such as 5-fluorouracil, irinotecan, and oxaliplatin provide high-value treatments. More modern agents targeting the EGFR or VEGF pathways, such as bevacizumab, cetuximab, and panitumumab, do not appear to be cost-effective treatments at their current costs. The analytical methods used within the papers varied widely, and this variation likely plays a significant role in the heterogeneity in incremental cost-effectiveness ratios. The cost-effectiveness of current treatment strategies for mCRC is highly variable. Drugs recently approved by the US Food and Drug Administration for mCRC are not cost-effective, and this is primarily driven by high drug costs.Entities:
Keywords: Chemotherapy; Colorectal cancer; Cost-effectiveness; Incremental cost effectiveness ratio; Value
Mesh：
Substances：
Year: 2015 PMID： 26541320 PMCID： PMC4744531 DOI： 10.1016/j.clcc.2015.10.002
Source DB: PubMed Journal: Clin Colorectal Cancer ISSN： 1533-0028 Impact factor: 4.481